TEXAS A&M UNIVERSITY-SAN ANTONIO

IBC Meeting Minutes **3-18-2026**
Virtual-committee members only

Members:	**ATTENDANCE**
Chris Mares, PhD	Chair, Scientist
T. Brock Symons, PhD	Non-Scientist
Donna Lehman, PhD	Scientist
George Perry, PhD	External Member (arrived 2:13pm)
Jorge Medina, PhD	External Member
Others:	
Rani Muthukrishnan, PhD	Executive Director of Research Compliance
Mary Jo Bilicek, MS	Sr. Research Compliance Coordinator
Victor Pantusa, MS	Invited Guest
Anthony Murph, MS	Invited Guest

MINUTES:

1. **Attendee count**
   - 1.1 4 in attendance, quorum attained**.**
   - 1.2 The meeting was called to order by the Chair at 2:02pm
   - 1.3 The Chair established all members acknowledged and agreed to the Confidentiality Statement.
   - 1.4 The Chair asked members to confirm no conflict of interest (COI).

5. **New Business**

Business containing work covered by *NIH Guidelines*

5.1 2025-07 *Biochemical studies on recombinant iron transport proteins from different bacteria*

The chair provided an overview of the revised protocol. This project explores new ways to treat breast and pancreatic cancers by using nanoparticles to deliver medicines directly to cancer cells. The PI wants to test these particles in both regular cell cultures and 3D models that better mimic real tumors, with the goal of making treatments more effective and reducing side effects.
The committee reviewed the submitted revisions. Lab inspection is pending for approval of this protocol which is scheduled.

Motion to approve pending successful lab inspection as verified by IBC chair, by J. Medina and seconded by T. Symons
Approved 5, abstained 0, rejected 0

5.2 2025-08 *Evaluation of Nanoparticle Therapeutics in 2D and 3D Cell Culture Models of Breast and Pancreatic Cancer*

The chair provided an overview of the revised protocol. This project will test whether nanoparticles can improve the way cancer drugs are delivered to cancer cells. Nanoparticles will be prepared in the lab, loaded with drugs, and applied to breast and pancreatic cancer cells. The cells will be grown in two formats: as single layers on plates (2D cultures) and as clusters that better mimic tumors (3D cultures). By studying how the cells respond, the researchers will learn if nanoparticle delivery makes the drugs work more effectively at smaller doses. RNA and proteins will be extracted measured using standard laboratory methods such as PCR, western blotting, and immunohistochemistry.

The committee discussed and identified several areas that needed to be clarified. How will the cells be manipulated? What type of nanoparticles will be used, are they carbon based and what is the procedure for synthesizing? Will autoclaving cells treated with the drugs present a problem with volatilization of the chemicals? Will any other chemoTx drugs will be used besides ones listed. How will the cells be loaded with the therapeutic?

Motion to table pending revisions by G. Perry and seconded by D. Lehman
Approved 5, abstained 0, rejected 0

Business NOT containing work covered by *NIH Guidelines* discussed

6. **Next Meeting:**
   April 22nd
   May 19-in Person Training
   Motion to adjourn meeting by J. Medina and seconded by G. Perry
   Approved 5, abstained 0, rejected 0
   Meeting adjourned at 2:56pm